DUBLIN, Jan. 5, 2024 /PRNewswire/ — The “GlaxoSmithKline Plc – Digital Transformation Strategies” company profile has been added to ResearchAndMarkets.com’s offering.
The report offers valuable insights into GlaxoSmithKline’s technology-related activities. It provides an understanding of the company’s digital transformation strategies and innovation programs. These initiatives are aimed at leveraging technology to enhance operations and competitiveness in the pharmaceutical and healthcare industry.
The report covers a range of technology initiatives, including partnerships, product launches, and investments, which signify the company’s commitment to staying at the forefront of technological advancements. Each initiative is detailed with information about the technology theme, objectives, and the benefits it aims to achieve.
This information helps in understanding the strategic rationale behind these endeavors. Additionally, the report provides details about GlaxoSmithKline’s estimated Information and Communication Technology (ICT) budgets, which are crucial for assessing the company’s commitment to technology investments. Furthermore, it may highlight any major ICT contracts or partnerships, shedding light on key technology providers or collaborators that play a significant role in the company’s tech-related endeavors.
The report provides information and insights into GlaxoSmithKline’s tech activities, including –
- Insights of its digital transformation strategies and innovation programs
- Overview of technology initiatives covering partnerships, product launches and investments
- Insights on each technology initiative including technology theme, objective, and benefits
- Details of estimated ICT budgets and major ICT contracts
Scope
- GSK uses artificial intelligence (AI) and machine learning (ML) to integrate population-scale datasets and observational cohorts with complex models to transform drug discovery. This process enables GSK’s scientists to quickly and accurately identify genetic variants linked to diseases..
- GSK is innovating in vaccine development by employing a ‘digital twin,’ a real-time simulation of the entire vaccine manufacturing process. In this closed-loop system, there is a constant exchange of insights between the real and virtual realms, which enables scientists to optimize the production process.
- The GSK Onyx Research Data Platform is a technology-driven initiative aimed at using data to discover treatments more efficiently. Onyx encompasses a suite of cutting-edge platforms designed to process and leverage vast amounts of data generated.
- In 2023, GSK India collaborated with PadUp Ventures for Hello Tomorrow, an educational boot camp for healthcare startups aiming to support innovative solutions and present graduating startups to the GSK India Leadership Team.
Reasons to Buy
- Gain insights into GSK’s tech operations.
- Gain insights into its tech strategies and innovation initiatives.
- Gain insights into its technology themes under focus.
- Gain insights into various product launches, partnerships and investment strategies.
Key Topics Covered:
- Overview
- Digital Transformation Strategy
- Accelerators, Incubators, and Other Innovation Programs
- Technology Focus
- Technology Initiatives
- Venture Arm: SR One
- Investment
- Partnership and Investment Network Map
- ICT Budget and Contracts
- Key Executives
- Contact the Publisher
For more information about this company profile visit https://www.researchandmarkets.com/r/2phnih
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
